PULSAR Combined With Immunotherapy for Unresectable Locally Advanced Gastric Cancer

ConditionsGastric Adenocarcinoma Stomach Neoplasms Locally Advanced Gastric Cancer Unresectable Gastric Cancer

Trial statusRecruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexAll

Age19+

SponsorSamsung Medical Center

About this trial

The purpose of this prospective, single-center, phase II study is to evaluate the clinical efficacy and safety of combining first-line systemic therapy plus immunotherapy with personalized ultrafractionated stereotactic adaptive radiation therapy (PULSAR) in patients with unresectable locally advanced gastric cancer.

Eligibility criteria

Qualifiers

None

Disqualifiers

None

Trial design

Treatments tested in this trial

PULSAR (Personalized Ultrafractionated Stereotactic Adaptive Radiation Therapy)
PULSAR

Treatment groups

53 Participants

are divided into 1 treatment group

Sponsors and collaborators

Samsung Medical Center

Lead sponsor

Source ClinicalTrials.gov